Table 2.
Baseline characteristics of PLWHIV vs. uninfected individuals
| PLWHIV (n=209) |
HIV uninfected (n=168) |
P value | |
|---|---|---|---|
| Total cholesterol, mg/dL | 170±48 | 182±42 | 0.09 |
| Trigylcerides, mg/dL | 172±148 | 148±104 | 0.09 |
| HDL, mg/dL | 44±22 | 52±19 | 0.01 |
| LDL, mg/dL | 92±38 | 101±37 | 0.14 |
| BMI, kg/m2 | 26±5.3 | 28±7.4 | 0.01 |
| Systolic Blood pressure, mmHg | 123±19 | 126±18 | 0.31 |
| Diastolic Blood pressure, mmHg | 75±11 | 74±11 | 0.42 |
| Heart Rate, beats/min | 83±17 | 83±16 | 0.99 |
| Creatinine, mg/dL | 1.1±1.2 | 1.1±1.2 | 0.85 |
| HCV co-infection | 38 (18) | ||
| Duration since HIV diagnosis (years) | 14±7 | ||
| Endocarditis | 6(3) | ||
| CD4 count (cells/mm3) | 378±358 | ||
| CD4 nadir (cells/mm3) | 184±194 | ||
| CD8 count (cells/mm3) | 825±550 | ||
| ART at time of CT | 194 (93) | ||
| NNRTI | 67 (32) | ||
| NRTI | 159 (76) | ||
| PI | 87 (42) | ||
| Integrase inhibitors | 23 (11) | ||
| Duration of ART (years) | 9.8 (4.9, 15.0) | ||
| Undetectable viral load (copies/ml) | 104 (49) |
*
Values are mean±SD, n (%) or median (IQR). HDL: high density lipoprotein, LDL: low density lipoprotein, BMI: body mass index, ART: antiretroviral therapy; NNRTI: non nucleotide reverse transcriptase inhibitors; NRTI: nucleotide reverse transcriptase inhibitors; PI: protease inhibitors